An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
NCT05835310
This study is recruiting at 20 US sites in 13 states, according to its ClinicalTrials.gov record last updated .
Summary
A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), Efficacy, and Safety of Anifrolumab in Children with Moderate to Severe Active Systemic Lupus Erythematosus (SLE)
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Systemic Lupus Erythematosus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 5 to 17 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- September 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Research Site · Phoenix, AZ
California · 1
- Research Site · Los Angeles, CA
District of Columbia · 1
- Research Site · Washington D.C., DC
Illinois · 2
- Research Site · Chicago, IL
- Research Site · Chicago, IL
Louisiana · 1
- Research Site · New Orleans, LA
Minnesota · 1
- Research Site · Saint Paul, MN
New York · 4
- Research Site · New Hyde Park, NY
- Research Site · New York, NY
- Research Site · The Bronx, NY
- Research Site · Valhalla, NY
North Carolina · 1
- Research Site · Durham, NC
Ohio · 3
- Research Site · Cincinnati, OH
- Research Site · Cleveland, OH
- Research Site · Columbus, OH
Oregon · 1
- Research Site · Portland, OR
Pennsylvania · 1
- Research Site · Philadelphia, PA
Texas · 2
- Research Site · El Paso, TX
- Research Site · Houston, TX
Utah · 1
- Research Site · Salt Lake City, UT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.